Kamada Reports Strong First Quarter 2024 Financial Results with Year-Over-Year Top-Line Growth of 23% and a 96% Increase in Profitability; Raises Full-Year Financial Guidance

Rhea-AI Summary

Kamada reported strong first quarter 2024 financial results with a 23% increase in revenues and a 96% rise in profitability. The company's top-line growth was driven by U.S. sales of KEDRAB® and CYTOGAM®. Kamada increased its full-year revenue guidance to $158-162 million and adjusted EBITDA to $28-32 million. The company remains optimistic about its growth prospects beyond 2024.

Positive

• Kamada reported a 23% increase in revenues for the first quarter of 2024 compared to the prior year, reaching $37.7 million.

• The adjusted EBITDA for the first quarter of 2024 was $7.5 million, representing a significant 96% increase year-over-year.

• The strong performance was attributed to the U.S. sales of KEDRAB® and CYTOGAM®, the company's key growth drivers.

• Kamada raised its full-year revenue guidance to $158-162 million and adjusted EBITDA to $28-32 million, reflecting confidence in continued growth throughout 2024.

• The company continues to explore new business development opportunities to sustain double-digit growth rates post-2024.

Negative

• The gross profit margin for the first quarter of 2024 was 44%, down from 39% in the prior year, indicating potential cost pressures.

• The net income for the first quarter of 2024 was $2.4 million, a significant improvement from the net loss of $1.8 million in the same period last year.

• Cash provided by operating activities was $1.0 million in the first quarter of 2024, a positive shift from cash used in operating activities of $2.9 million in the first quarter of 2023.

• The decrease in cash balance from $55.6 million on December 31, 2023, to $48.2 million on March 31, 2024, may raise concerns about capital investments and long-term liabilities.

Financial Analyst

Kamada Ltd.'s first-quarter financial results for 2024 show a robust performance, with a 23% increase in revenue and an impressive 96% increase in Adjusted EBITDA. Particularly noteworthy is the company's gross margin improvement to 44%, up from 39% in the prior year. Increased demand for CYTOGAM in the U.S. and higher sales of KEDRAB contributed significantly to these results. The company's decision to raise its full-year revenue guidance suggests confidence in sustained momentum and continued market penetration of its key products. Investors should also take note of the strategic capital investments, like the construction of a new plasma collection center, indicating a commitment to long-term growth. While the capital investments have led to a decrease in cash balance from the previous year, such expenditure is typical for companies in growth phases and is often viewed as a positive indicator for future revenue streams. The forecast for double-digit growth in top- and bottom-line figures is an additional positive signal for investors, implying that Kamada is scaling operations efficiently while capitalizing on its market position.

Medical Research Analyst

The ongoing pivotal Phase 3 InnovAATe clinical trial for inhaled Alpha-1 Antitrypsin therapy, a potential treatment for AAT Deficiency, is of considerable interest. The FDA's inclination to potentially accept a P<0.1 alpha level for the primary endpoint could expedite the program's progress. This development demonstrates Kamada's solid pipeline and potential expansion in its specialty plasma-derived portfolio. The successful launch of BEVACIZUMAB KAMADA, a biosimilar to Avastin®, in Israel marks Kamada's growing presence in the oncology biosimilars market, which could provide a new revenue stream and help diversify its product portfolio. For investors, these clinical and commercial developments suggest a proactive approach in both expanding the company's product offerings and navigating regulatory pathways to bring treatments to market more efficiently.

Market Research Analyst

The biopharmaceutical sector, particularly companies like Kamada specializing in rare and serious conditions, operates in a high-barrier market with substantial growth potential. Kamada's strategic focus on the U.S. market, where healthcare spending is generally higher, has paid dividends as evidenced by its top-line growth. The increased full-year financial guidance indicates not only operational excellence but also adept market forecasting and product demand anticipation. The positive financial outcomes reflect not just current performance but also strategic positioning for future growth, which is critical for investors looking at the long-term potential of their investments. With the recent FDA interactions and the launch of a biosimilar in Israel, Kamada is demonstrating its ability to navigate complex regulatory environments and commercialize its products effectively.

• Revenues for First Quarter of 2024 were $37.7 Million, Representing a 23% Increase Year-over-Year
• First Quarter 2024 Adjusted EBITDA of $7.5 Million, Representing a 96% Increase Year-over-Year
• Momentum Primarily Driven by U.S. Sales of the Company’s Two Most Significant Catalysts, KEDRAB® and CYTOGAM®
• Strong First Quarter Results and Positive Outlook for Remainder of 2024 Support Increase of Full-Year Revenue Guidance to $158 Million-$162 Million and Adjusted EBITDA to $28 Million-$32 Million
• Conference Call and Live Webcast Today at 8:30 AM ET

REHOVOT, Israel and HOBOKEN, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced financial results for three months ended March 31, 2024.

“We are excited by our strong financial and operational start to 2024, which has us well-positioned for a highly successful year,” said Amir London, Kamada’s Chief Executive Officer. “Total revenues for the first quarter of 2024 were $37.7 million, representing a 23% increase year-over-year, and adjusted EBITDA was $7.5 million, nearly double as compared to the first quarter of last year and representing a 20% margin of revenues. While we benefit from the strength of our entire portfolio, we continue to effectively leverage the two most important growth drivers in our business, KEDRAB® and CYTOGAM®. For CYTOGAM, our active promotion of the product, supported by recently published new clinical data, is driving increased demand, and we are encouraged by the continued growth being demonstrated by KEDRAB.”

“Based on our strong performance in the first quarter and our expectation for the continued momentum in our business throughout 2024, we are raising our full-year 2024 revenue guidance to be between $158 million to $162 million from the previous forecast of $156 million to $160 million. We are also increasing our adjusted EBITDA guidance to $28 million to $32 million from the initial guidance of $27 million to $30 million. Importantly, we continue to pursue compelling new business development opportunities, leveraging our overall financial strength. These opportunities are expected to support continued growth at double-digit rates beyond 2024,” added Mr. London.

“Patient enrollment continues in our ongoing pivotal Phase 3 InnovAATe clinical trial for the inhaled Alpha-1 Antitrypsin therapy for the treatment of AAT Deficiency. Following recent positive feedback from the U.S. Food and Drug Administration (FDA) through which the FDA expressed its willingness to potentially accept a P<0.1 alpha level in evaluating InnovAATe for meeting the efficacy primary endpoint for registration, we recently filed an IND amendment with both a revised Statistical Analysis Plan (SAP) and study protocol, and we expect further FDA feedback during the second half of 2024. If approved, these changes may allow for the acceleration of the program,” concluded Mr. London.

Financial Highlights for the Three Months Ended March 31, 2024

• Total revenues were $37.7 million in the first quarter of 2024, a 23% increase from the prior year period. The increase in revenues was primarily attributable to increased sales of CYTOGAM due to increased demand for the product in the U.S. market, as well as increased sales of KEDRAB to Kedrion due to increased market share in the U.S.
• Gross profit and gross margins were $16.8 million and 44%, respectively, in the first quarter of 2024, compared to $11.9 million and 39%, respectively, reported in the prior year period. Cost of goods sold in the Company’s Proprietary segment for each of the first quarter of 2024 and 2023 included $1.3 million of depreciation expenses associated with intangible assets generated through the IgG products acquisition.
• Operating expenses, including R&D, Sales & Marketing (S&M), G&A and other expenses, totaled $12.7 million in the first quarter of 2024, as compared to $11.6 million in the first quarter of 2023. S&M costs for the first quarter of 2024 and 2023 included $0.4 million of amortization expenses of intangible assets generated through the IgG products acquisition.
• Net income was $2.4 million, or $0.04 per share, in the first quarter of 2024, as compared to a net loss of $1.8 million, or $(0.04) per share, in the first quarter of 2023.
• Adjusted EBITDA, as detailed in the tables below, was $7.5 million in the first quarter of 2024, a 96% increase from the $3.8 million in the first quarter of 2023.
• Cash provided by operating activities was $1.0 million in the first quarter of 2024, as compared to cash used in operating activities of $2.9 million in the first quarter of 2023.

Balance Sheet Highlights

As of March 31, 2024, the Company had cash, cash equivalents, and short-term investments of $48.2 million, as compared to $55.6 million on December 31, 2023. The decrease in cash balance was attributable to capital investments made with respect to the construction of our new plasma collection center in Uvalde, Texas, and payment on account of long-term liabilities associated with the acquisition completed in November 2021.

Recent Corporate Highlights

• During the first quarter of 2024, Kamada completed the successful launch in Israel of BEVACIZUMAB KAMADA, the biosimilar to Avastin®, which is indicated for the treatment of certain types of cancer, including colon cancer and metastatic breast cancer. This represents the first biosimilar product to be launched and distributed by Kamada in Israel. The product is manufactured by mAbxience Research S.L., from Madrid, Spain.

Fiscal Year 2024 Guidance

Based on the Company’s strong performance in the first quarter and its expectation for continued momentum in the business throughout 2024, Kamada is increasing its fiscal year 2024 total revenue guidance from a range of $156 million to $160 million to a range of $158 million to $162 million, and adjusted EBITDA from a range of $27 million to $30 million to a range of $28 million to $32 million, representing double digit top- and bottom-line growth year-over-year.

Conference Call

Kamada management will host an investment community conference call today, Wednesday, May 8, 2024, at 8:30am Eastern Time to present the Company’s results and answer questions. Shareholders and other interested parties may participate in the conference call by dialing 1-888-886-7786 (from within the U.S.) or 1-809-468-221 (from Israel), or 1-416-764-8658 (International) and entering the conference ID 31202863. The call will also be webcast live on the Internet at https://viavid.webcasts.com/starthere.jsp?ei=1665369&tp_key=952bd14ce0.

Non-IFRS financial measures

We present EBITDA and adjusted EBITDA because we use these non-IFRS financial measures to assess our operational performance, for financial and operational decision-making, and as a means to evaluate period-to-period comparisons on a consistent basis. Management believes these non-IFRS financial measures are useful to investors because: (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making and provide investors with a meaningful perspective on the current underlying performance of the Company’s core ongoing operations; and (2) they exclude the impact of certain items that are not directly attributable to our core operating performance and that may obscure trends in the core operating performance of the business. Non-IFRS financial measures have limitations as an analytical tool and should not be considered in isolation from, or as a substitute for, our IFRS results. We expect to continue reporting non-IFRS financial measures, adjusting for the items described below, and we expect to continue to incur expenses similar to certain of the non-cash, non-IFRS adjustments described below. Accordingly, unless otherwise stated, the exclusion of these and other similar items in the presentation of non-IFRS financial measures should not be construed as an inference that these items are unusual, infrequent or non-recurring. EBITDA and adjusted EBITDA are not recognized terms under IFRS and do not purport to be an alternative to IFRS terms as an indicator of operating performance or any other IFRS measure. Moreover, because not all companies use identical measures and calculations, the presentation of EBITDA and adjusted EBITDA may not be comparable to other similarly titled measures of other companies. EBITDA is defined as net income (loss), plus income tax expense, plus or minus financial income or expenses, net, plus or minus income or expense in respect of securities measured at fair value, net, plus or minus income or expenses in respect of currency exchange differences and derivatives instruments, net, plus depreciation and amortization expense, whereas adjusted EBITDA is the EBITDA plus non-cash share-based compensation expenses and certain other costs.

For the projected 2024 adjusted EBITDA information presented herein, the Company is unable to provide a reconciliation of this forward measure to the most comparable IFRS financial measure because the information for these measures is dependent on future events, many of which are outside of the Company’s control. Additionally, estimating such forward-looking measures and providing a meaningful reconciliation consistent with the Company’s accounting policies for future periods is meaningfully difficult and requires a level of precision that is unavailable for these future periods and cannot be accomplished without unreasonable effort. Forward-looking non-IFRS measures are estimated in a manner consistent with the relevant definitions and assumptions noted in the Company’s adjusted EBITDA for historical periods.

About Kamada

Kamada Ltd. (the “Company”) is a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, focused on diseases of limited treatment alternatives. The Company is also advancing an innovative development pipeline targeting areas of significant unmet medical need. The Company’s strategy is focused on driving profitable growth from its significant commercial catalysts as well as its manufacturing and development expertise in the plasma-derived and biopharmaceutical fields. The Company’s commercial products portfolio includes six FDA approved plasma-derived biopharmaceutical products: CYTOGAM®, KEDRAB®, WINRHO SDF®, VARIZIG®, HEPAGAM B® and GLASSIA®, as well as KAMRAB®, KAMRHO (D)® and two types of equine-based anti-snake venom (ASV) products. The Company distributes its commercial products portfolio directly, and through strategic partners or third-party distributors in more than 30 countries, including the U.S., Canada, Israel, Russia, Argentina, Brazil, India, Australia and other countries in Latin America, Europe, the Middle East, and Asia. The Company leverages its expertise and presence in the Israeli market to distribute, for use in Israel, more than 25 pharmaceutical products that are supplied by international manufacturers. During recent years the Company added eleven biosimilar products to its Israeli distribution portfolio, which, subject to the European Medicines Agency (EMA) and the Israeli Ministry of Health approvals, are expected to be launched in Israel through 2028. The Company owns an FDA licensed plasma collection center in Beaumont, Texas, which currently specializes in the collection of hyper-immune plasma used in the manufacture of KAMRHO (D), KARAB and KEDRAB. In addition to the Company’s commercial operation, it invests in research and development of new product candidates. The Company’s leading investigational product is an inhaled AAT for the treatment of AAT deficiency, for which it is continuing to progress the InnovAATe clinical trial, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial. FIMI Opportunity Funds, the leading private equity firm in Israel, is the Company’s controlling shareholder, beneficially owning approximately 38% of the outstanding ordinary shares.

Cautionary Note Regarding Forward-Looking Statements

This release includes forward-looking statements within the meaning of Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, including statements regarding: 1) positive outlook for reminder of 2024, 2) anticipation of continued momentum through 2024 and continued growth at double-digit rates beyond 2024, 3) Full-Year Revenue Guidance to be between $158 Million-$162 Million and Adjusted EBITDA to be between $28 Million-$32 Million, 4) being well-positioned for a highly successful year, 5) continuing to maintain the overall financial strength supporting us in pursuing compelling new business development opportunities which would accelerate the growth and profitability of our existing business beyond 2024, 6) continued enrollment in pivotal phase 3 InnovAATe clinical trial, and 7) our expectations to receive FDA feedback to the IND amendment during the second half of 2024, which, if approved, may allow for the acceleration of the InnovAATe program. Forward-looking statements are based on Kamada’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to the evolving nature of the conflicts in the Middle East and the impact of such conflicts in Israel, the Middle East and the rest of the world, the impact of these conflicts on market conditions and the general economic, industry and political conditions in Israel, the U.S. and globally, continuation of inbound and outbound international delivery routes, continued demand for Kamada’s products, financial conditions of the Company’s customer, suppliers and services providers, Kamada’s ability to integrate the new product portfolio into its current product portfolio, Kamada’s ability to grow the revenues of its new product portfolio, and leverage and expand its international distribution network, ability to reap the benefits of the acquisition of the plasma collection center, including the ability to open additional U.S. plasma centers, and acquisition of the FDA-approved plasma-derived hyperimmune commercial products, the ability to continue enrollment of the pivotal Phase 3 InnovAATe clinical trial, unexpected results of clinical studies, Kamada’s ability to manage operating expenses, additional competition in the markets that Kamada competes, regulatory delays, prevailing market conditions and the impact of general economic, industry or political conditions in the U.S., Israel or otherwise, and other risks detailed in Kamada’s filings with the U.S. Securities and Exchange Commission (the “SEC”) including those discussed in its most recent Annual Report on Form 20-F and in any subsequent reports on Form 6-K, each of which is on file or furnished with the SEC and available at the SEC’s website at www.sec.gov. The forward-looking statements made herein speak only as of the date of this announcement and Kamada undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

CONTACTS:

Chaime Orlev
Chief Financial Officer
IR@kamada.com

Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
britchie@LifeSciAdvisors.com

CONDENCED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITTION
		As of								As of
		March 31,								December 31,
		2024				2023				2023
		Unaudited								Audited
Assets
Current Assets
Cash and cash equivalents		$	48,194			$	27,121			$	55,641
Trade receivables, net			18,855				20,925				19,877
Other accounts receivables			6,411				3,603				5,965
Inventories			84,348				79,754				88,479
Total Current Assets			157,808				131,403				169,962
Non-Current Assets
Property, plant and equipment, net			30,727				26,496				28,224
Right-of-use assets			7,632				5,836				7,761
Intangible assets, Goodwill and other long-term assets			138,623				145,305				140,465
Contract assets			8,384				7,755				8,495
Total Non-Current Assets			185,366				185,392				184,945
Total Assets		$	343,174			$	316,795			$	354,907
Liabilities
Current Liabilities
Current maturities of bank loans		$	-			$	4,444			$	-
Current maturities of lease liabilities			1,467				1,438				1,384
Current maturities of other long-term liabilities			12,980				29,414				14,996
Trade payables			16,492				26,210				24,804
Other accounts payables			6,210				7,350				8,261
Deferred revenues			26				419				148
Total Current Liabilities			37,175				69,275				49,593
Non-Current Liabilities
Bank loans			-				11,852				-
Lease liabilities			7,278				4,992				7,438
Contingent consideration			16,760				18,115				18,855
Other long-term liabilities			34,842				37,280				34,379
Employee benefit liabilities, net			609				473				621
Total Non-Current Liabilities			59,489				72,712				61,293
Shareholder’s Equity
Ordinary shares			15,022				11,736				15,021
Additional paid in capital net			266,183				210,665				265,848
Capital reserve due to translation to presentation currency			(3,490	)			(3,490	)			(3,490	)
Capital reserve from hedges			12				(99	)			140
Capital reserve from share-based payments			6,336				5,750				6,427
Capital reserve from employee benefits			282				539				275
Accumulated deficit			(37,835	)			(50,293	)			(40,200	)
Total Shareholder’s Equity			246,510				174,808				244,021
Total Liabilities and Shareholder’s Equity		$	343,174			$	316,795			$	354,907

CONDENCED CONSOLIDATED INTERIM OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
		Three months period ended								Year ended
		March 31,								December 31,
		2024				2023				2023
		Unaudited								Audited
Revenues from proprietary products		$	33,758			$	24,061			$	115,458
Revenues from distribution			3,978				6,649				27,061
Total revenues			37,736				30,710				142,519
Cost of revenues from proprietary products			17,620				13,224				63,342
Cost of revenues from distribution			3,365				5,647				23,687
Total cost of revenues			20,985				18,871				87,029
Gross profit			16,751				11,839				55,490
Research and development expenses			4,295				3,231				13,933
Selling and marketing expenses			4,631				3,922				16,193
General and administrative expenses			3,786				3,418				14,381
Other expenses			-				979				919
Operating income (loss)			4,039				289				10,064
Financial income			280				25				588
Income (expenses) in respect of currency exchange differences and derivatives instruments, net			124				151				55
Financial Income (expense) in respect of contingent consideration and other long- term liabilities.			(1,845	)			(1,761	)			(980	)
Financial expenses			(159	)			(500	)			(1,298	)
Income before tax on income			2,439				(1,796	)			8,429
Taxes on income			74				13				145
Net Income (loss)		$	2,365			$	(1,809	)		$	8,284
Other Comprehensive Income (loss):
Amounts that will be or that have been reclassified to profit or loss when specific conditions are met
Gain (loss) on cash flow hedges			(71	)			(156	)			(186	)
Net amounts transferred to the statement of profit or loss for cash flow hedges			(57	)			145				414
Items that will not be reclassified to profit or loss in subsequent periods:
Remeasurement gain (loss) from defined benefit plan			7				191				(73	)
Total comprehensive income (loss)		$	2,244			$	(1,629	)		$	8,439
Earnings per share attributable to equity holders of the Company:
Basic net earnings per share		$	0.04			$	(0.04	)		$	0.17
Diluted net earnings per share		$	0.04			$	(0.04	)		$	0.15

CONDENCED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS
		Three months period Ended								Year Ended
		March 31,								December 31,
		2024				2023				2023
		Unaudited								Audited
Cash Flows from Operating Activities
Net income (loss)		$	2,365			$	(1,809	)		$	8,284
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Adjustments to the profit or loss items:
Depreciation and amortization			3,237				3,123				12,714
Financial expenses (income), net			1,600				2,085				1,635
Cost of share-based payment			241				415				1,314
Taxes on income			74				13				145
Loss (gain) from sale of property and equipment			-				(22	)			(5	)
Change in employee benefit liabilities, net			(4	)			(8	)			(125	)
			5,148				5,606				15,678
Changes in asset and liability items:
Decrease (increase) in trade receivables, net			610				6,306				7,835
Decrease (increase) in other accounts receivables			(516	)			1,362				(1,150	)
Decrease (increase) in inventories			4,131				(10,970	)			(19,694	)
Decrease (increase) in deferred expenses			112				3,554				2,814
Decrease (increase) in trade payables			(8,785	)			(6,712	)			(8,885	)
Decrease (increase) in other accounts payables			(2,051	)			(238	)			765
Decrease (increase) in deferred revenues			(122	)			384				113
			(6,621	)			(6,314	)			(18,202	)
Cash received (paid) during the period for:
Interest paid			(129	)			(341	)			(1,228	)
Interest received			280				25				-
Taxes paid			(23	)			(18	)			(217	)
			128				(334	)			(1,445	)
Net cash provided by (used in) operating activities		$	1,020			$	(2,851	)		$	4,315

CONDENCED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS (continued)
		Three months period Ended								Year Ended
		March, 31								December 31,
		2024				2023				2023
		Unaudited								Audited
Cash Flows from Investing Activities
Purchase of property and equipment and intangible assets		$	(2,682	)		$	(1,117	)		$	(5,850	)
Proceeds from sale of property and equipment			-				24				7
Net cash provided by (used in) investing activities			(2,682	)			(1,093	)			(5,843	)
Cash Flows from Financing Activities
Proceeds from exercise of share base payments			1				1				4
Proceeds from issuance of ordinary shares, net			-				-				58,231
Repayment of lease liabilities			(244	)			(271	)			(850	)
Repayment of long-term loans			-				(1,111	)			(17,407	)
Repayment of other long-term liabilities			(5,496	)			(1,500	)			(17,300	)
Net cash provided by (used in) financing activities			(5,739	)			(2,881	)			22,678
Exchange differences on balances of cash and cash equivalent			(46	)			(312	)			233
Increase (decrease) in cash and cash equivalents			(7,447	)			(7,137	)			21,383
Cash and cash equivalents at the beginning of the period			55,641				34,258				34,258
Cash and cash equivalents at the end of the period		$	48,194			$	27,121			$	55,641
Significant non-cash transactions
Right-of-use asset recognized with corresponding lease liability		$	306			$	3,580			$	6,546
Purchase of property and equipment and Intangible assets		$	905			$	292			$	646

NON-IFRS MEASURES – ADJUSTED EBITDA
		Three months period Ended								Year ended
		March 31,								December 31,
		2024				2023				2023
		U.S. Dollars in thousands
Net (loss) income		$	2,365			$	(1,809	)		$	8,284
Taxes on income			74				13				145
Financial expense (income), net			1,600				2,085				1,635
Depreciation and amortization expense			3,237				3,123				12,714
Non-cash share-based compensation expenses			241				415				1,314
Adjusted EBITDA		$	7,517			$	3,827			$	24,092

FAQ

What were Kamada's revenues for the first quarter of 2024?

Kamada reported revenues of $37.7 million for the first quarter of 2024, representing a 23% increase year-over-year.

What is Kamada's adjusted EBITDA for the first quarter of 2024?

Kamada's adjusted EBITDA for the first quarter of 2024 was $7.5 million, reflecting a 96% increase compared to the prior year.

What led to the increase in Kamada's revenues for the first quarter of 2024?

The increase in revenues was mainly driven by strong U.S. sales of KEDRAB® and CYTOGAM®.

What is Kamada's full-year revenue guidance for 2024?

Kamada raised its full-year revenue guidance to $158-162 million for 2024.

What does Kamada plan to do beyond 2024 for sustaining growth?

Kamada aims to explore new business development opportunities to support double-digit growth rates beyond 2024.